Six weeks after Rwanda-backed rebels captured the eastern Congolese cities of Goma and Bukavu, the region is facing a setback ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

The Eastern Democratic Republic of the Congo is suffering a severe setback in its fight against the Mpox outbreak, six weeks ...

Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.

The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox,” said Past ACTG Chair Judith Currier M.D., M.Sc. “There was considerable ...

Dr. Alex Isakov offers updates and insights for EMS professionals on navigating the infectious disease landscape ...

AP Hospitals across eastern Congo that were once at the forefront of the country’s response to the mpox outbreak are facing a setback in detecting the disease and offering treatment following the ...

A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.

Nurses are administering medicine to Mpox patients at a tent in Kabare, Democratic Republic of the Congo, as the area ...

NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...